BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 25080476)

  • 1. Hematogenous dissemination of glioblastoma multiforme.
    Müller C; Holtschmidt J; Auer M; Heitzer E; Lamszus K; Schulte A; Matschke J; Langer-Freitag S; Gasch C; Stoupiec M; Mauermann O; Peine S; Glatzel M; Speicher MR; Geigl JB; Westphal M; Pantel K; Riethdorf S
    Sci Transl Med; 2014 Jul; 6(247):247ra101. PubMed ID: 25080476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioblastomas in the older old.
    Kleinschmidt-DeMasters BK; Lillehei KO; Varella-Garcia M
    Arch Pathol Lab Med; 2005 May; 129(5):624-31. PubMed ID: 15859633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma.
    Stichel D; Ebrahimi A; Reuss D; Schrimpf D; Ono T; Shirahata M; Reifenberger G; Weller M; Hänggi D; Wick W; Herold-Mende C; Westphal M; Brandner S; Pfister SM; Capper D; Sahm F; von Deimling A
    Acta Neuropathol; 2018 Nov; 136(5):793-803. PubMed ID: 30187121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma.
    Gállego Pérez-Larraya J; Paris S; Idbaih A; Dehais C; Laigle-Donadey F; Navarro S; Capelle L; Mokhtari K; Marie Y; Sanson M; Hoang-Xuan K; Delattre JY; Mallet A
    Cancer; 2014 Dec; 120(24):3972-80. PubMed ID: 25139333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of chromosome 7, chromosome 10 and EGFR gene amplification in glioblastoma multiforme.
    Lopez-Gines C; Cerda-Nicolas M; Gil-Benso R; Pellin A; Lopez-Guerrero JA; Callaghan R; Benito R; Roldan P; Piquer J; Llacer J; Barbera J
    Clin Neuropathol; 2005; 24(5):209-18. PubMed ID: 16167544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.
    Smith JS; Tachibana I; Passe SM; Huntley BK; Borell TJ; Iturria N; O'Fallon JR; Schaefer PL; Scheithauer BW; James CD; Buckner JC; Jenkins RB
    J Natl Cancer Inst; 2001 Aug; 93(16):1246-56. PubMed ID: 11504770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet-derived growth factor receptor α/glial fibrillary acidic protein expressing peritumoral astrocytes associate with shorter median overall survival in glioblastoma patients.
    Leiss L; Mega A; Olsson Bontell T; Nistér M; Smits A; Corvigno S; Rahman MA; Enger PØ; Miletic H; Östman A
    Glia; 2020 May; 68(5):979-988. PubMed ID: 31769546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of epithelial and keratin markers in glioblastoma multiforme: an immunohistochemical study.
    Oh D; Prayson RA
    Arch Pathol Lab Med; 1999 Oct; 123(10):917-20. PubMed ID: 10506444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of amplified DNA sequences by reverse chromosome painting using genomic tumor DNA as probe.
    Joos S; Scherthan H; Speicher MR; Schlegel J; Cremer T; Lichter P
    Hum Genet; 1993 Feb; 90(6):584-9. PubMed ID: 8383093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma.
    Diamandis P; Ferrer-Luna R; Huang RY; Folkerth RD; Ligon AH; Wen PY; Beroukhim R; Ligon KL; Ramkissoon SH
    Diagn Pathol; 2016 Jan; 11():13. PubMed ID: 26817999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting epidermal growth factor receptor gene amplification status in glioblastoma multiforme by quantitative enhancement and necrosis features deriving from conventional magnetic resonance imaging.
    Dong F; Zeng Q; Jiang B; Yu X; Wang W; Xu J; Yu J; Li Q; Zhang M
    Medicine (Baltimore); 2018 May; 97(21):e10833. PubMed ID: 29794775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of the main genetic markers in glioblastoma multiforme is independent of tumor topology.
    Necesalová E; Vranová V; Kuglík P; Cejpek P; Jarosová M; Pesáková M; Relichová J; Veselská R
    Neoplasma; 2007; 54(3):212-8. PubMed ID: 17447852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple bone metastases from glioblastoma multiforme without local brain relapse: a case report and review of the literature.
    Takanen S; Bangrazi C; Caiazzo R; Raffetto N; Tombolini V
    Tumori; 2013; 99(5):e237-40. PubMed ID: 24362877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current data and strategy in glioblastoma multiforme.
    Iacob G; Dinca EB
    J Med Life; 2009; 2(4):386-93. PubMed ID: 20108752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme.
    Yin D; Ogawa S; Kawamata N; Leiter A; Ham M; Li D; Doan NB; Said JW; Black KL; Phillip Koeffler H
    Oncogene; 2013 Feb; 32(9):1155-63. PubMed ID: 22580610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?
    Armocida D; Pesce A; Frati A; Santoro A; Salvati M
    J Neurooncol; 2020 Jan; 146(2):275-284. PubMed ID: 31889239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MET immunolabelling is a useful predictive tool for MET gene amplification in glioblastoma.
    Burel-Vandenbos F; Ngo-Mai M; Dadone B; Di Mauro I; Gimet S; Saada-Bouzid E; Bourg V; Almairac F; Fontaine D; Virolle T; Pedeutour F
    Neuropathol Appl Neurobiol; 2017 Apr; 43(3):252-266. PubMed ID: 26946354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum concentrations of glial fibrillary acidic protein (GFAP) do not indicate tumor recurrence in patients with glioblastoma.
    Vietheer JM; Rieger J; Wagner M; Senft C; Tichy J; Foerch C
    J Neurooncol; 2017 Oct; 135(1):193-199. PubMed ID: 28717884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Systemic metastasis at the time of diagnosis of a glioblastoma].
    Montagne K; Marie B; Cahn V; Hennequin V; Didelot A; N'Seir R; Beauchesne P; Grignon Y
    Ann Pathol; 2004 Jun; 24(3):268-70. PubMed ID: 15480263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.